Prevalence and Clinical Significance of Monogenic Gene Mutations in High-Risk Patients With Urolithiasis: A Prospective Cross-Sectional Next-Generation Sequencing Study
This prospective study of 143 urolithiasis patients reveals that high-confidence monogenic gene mutations are significantly more prevalent in high-risk individuals, particularly those with recurrent stone formation, supporting the use of targeted genetic testing to guide personalized management.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Kidney stones are a common and painful problem, affecting roughly one in seven people over a lifetime. For decades, doctors have understood that these hard mineral deposits form when the urine becomes too concentrated with certain substances, often due to diet, dehydration, or metabolic quirks. The standard approach to prevention involves dietary changes and medication to balance these chemicals. However, a growing body of evidence suggests that for many patients, the root cause lies deeper, written in the very code of their cells. Just as some families are prone to high blood pressure or diabetes, some families carry specific genetic instructions that make their kidneys more likely to produce stones. These instructions, known as monogenic mutations, are single errors in a gene that disrupt how the body handles minerals. While these genetic causes were once thought to be rare and limited to children, modern technology now allows scientists to look for them in adults, raising a critical question: how many adults with kidney stones are actually dealing with a hereditary condition that standard tests might miss?
A team of researchers at Yonsei University in Seoul decided to answer this question by looking directly at the genetic code of patients with kidney stones. They recruited 143 adults who had been diagnosed with stones confirmed by imaging scans. To find the hidden genetic causes, the team used a powerful technology called next-generation sequencing. This method acts like a high-speed scanner, reading the DNA from a simple blood sample to check for errors in 47 specific genes known to be involved in kidney stone formation. The researchers did not treat all patients the same; instead, they split them into two groups based on their medical history. The first group, labeled "high-risk," included people who had formed stones multiple times, developed them at a young age (under 40), or had a family history of the disease. The second group, labeled "low-risk," consisted of people who were found to have stones incidentally while being checked for other kidney issues, with no history of recurrence or early onset.
The results of this genetic scan revealed a striking difference between the two groups. In the high-risk group, the researchers found that 57.3% of the patients carried a high-confidence genetic mutation that was strongly linked to kidney stone disease. When looking at the entire group of 143 patients, nearly 40 percent had these high-confidence genetic errors. In contrast, the low-risk group showed a much lower rate of these mutations. The study found that the single strongest predictor of having a genetic cause was not age or gender, but simply the history of forming stones again and again. Patients who suffered from recurrent stones were about six times more likely to carry a pathogenic mutation than those who did not. This suggests that for patients who keep coming back with new stones, the problem is often not just a lifestyle issue or a temporary metabolic imbalance, but a fundamental genetic instruction that needs to be identified.
The researchers also examined the chemical makeup of the stones and the patients' blood and urine levels. They found that while high-risk patients were more likely to have high levels of calcium in their urine, the standard blood and urine tests did not always reveal the full picture. Many patients with confirmed genetic mutations had metabolic results that looked normal or only slightly off, which could easily lead a doctor to miss the underlying genetic cause if they relied on these tests alone. The study identified a wide variety of genetic errors, affecting how the body handles calcium, oxalate, and cystine. One specific case highlighted in the research involved a man who had undergone multiple surgeries for recurring stones. Standard tests had not provided a clear answer, but the genetic test identified a specific mutation linked to a rare metabolic disorder. This discovery allowed doctors to switch his treatment plan to a targeted therapy that addressed the root cause rather than just managing the symptoms.
These findings suggest that the current approach to kidney stones may need to evolve for certain patients. The study indicates that genetic testing is not necessary for everyone, but it is highly valuable for those with specific warning signs, particularly a history of repeated stone formation. By identifying the genetic error, doctors can move beyond guesswork and offer personalized prevention strategies that target the specific metabolic defect. This could prevent future surgeries, protect kidney function, and provide answers for families worried about passing the condition to their children. While the study was conducted at a single hospital and focused on a specific set of genes, the data provides a clear roadmap for when genetic testing should be considered. It confirms that for a significant number of adults with difficult-to-treat kidney stones, the answer lies in their DNA, and finding that answer can change the course of their treatment.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.